Active Ingredient(s): Elapegademase-lvlr
FDA Approved: * October 5, 2018
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Revcovi Overview

Adenosine deaminase deficiency (ADA deficiency) is a metabolic disorder that causes immunodeficiency. It is caused by mutations in the ADA gene. It accounts for about 10–15% of all cases of autosomal recessive forms of severe combined immunodeficiency (SCID) among non-inbred populations.[1] ADA deficiency can present in infancy, childhood, adolescence, or adulthood. Age of onset and severity is related to some 29 known genotypes associated with the disorder.[2...

Read more Revcovi Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Revcovi Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 1.6mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Revcovi: (2 results)

Sorted by National Drug Code
  • 10122-502 Revcovi 1.6 mg/ml Intramuscular Injection by Chiesi USA, Inc.
  • 57665-002 Revcovi 1.6 mg/ml Intramuscular Injection by Leadiant Biosciences, Inc.

Other drugs which contain Elapegademase-lvlr or a similar ingredient: (1 result)